Cytomegalovirus retinitis after golidocitinib therapy in a patient with cutaneous T-cell lymphoma: a case report

The expanding use of biologic and targeted immunomodulatory therapies has been accompanied by an increasing number of reports of opportunistic ocular infections. Cytomegalovirus (CMV) retinitis (CMVR), in particular, has recently been reported after exposure to several Janus kinase (JAK) inhibitors, raising concern about a potential class-related ocular safety signal. We report a case of CMVR following exposure to golidocitinib, a selective JAK1 inhibitor, in an immunocompromised patient without human immunodeficiency virus (HIV) infection, in whom undetectable plasma CMV DNA contributed to delayed diagnosis. A 62-year-old HIV-negative man with relapsed primary cutaneous T-cell lymphoma (CTCL) and diabetes developed CMV viremia after four cycles of a golidocitinib-containing regimen. Golidocitinib was discontinued, and intravenous ganciclovir rendered plasma CMV DNA undetectable. During maintenance antiviral therapy, he developed progressive bilateral visual loss while weekly plasma testing remained negative. Early fundus photographs showed the classic “ketchup-and-cheese” appearance of fulminant CMVR, but diabetic retinopathy was diagnosed because of his diabetes and negative plasma CMV DNA result. This misdiagnosis delayed treatment for one month. At referral, visual acuity was hand motion in the right eye and 20/133 in the left eye, with severe vitritis, retinal vascular whitening, and disruption of the retinal layers. Subsequent intraocular fluid testing showed a vitreous CMV DNA level of 4.25 × 10 4 copies/mL, and targeted next-generation sequencing detected CMV. Subsequent systemic and intravitreal ganciclovir controlled the retinitis, but vision did not recover. To the best of our knowledge, this is the first published case report describing CMVR occurring after golidocitinib therapy. Undetectable plasma CMV DNA does not exclude compartmentalized ocular infection and should not delay intraocular fluid testing when necrotizing retinitis is suspected.

Authors

Institutions

Publication Details

Journal
BMC Ophthalmology
Published
2026-11-13
DOI
https://doi.org/10.1186/s12886-026-05532-y
Primary Topic
Cytomegalovirus and herpesvirus research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cytomegalovirus retinitis after golidocitinib therapy in a patient with cutaneous T-cell lymphoma: a case report

Xinyi Zhao, Qian Wang, Xueyun Zhang, Shuhao Fu
1 links
BMC Ophthalmology
Cytomegalovirus and herpesvirus research
article

Cytomegalovirus retinitis after golidocitinib therapy in a patient with cutaneous T-cell lymphoma: a case report

Xinyi Zhao, Qian Wang, Xueyun Zhang, Shuhao Fu
article en

Abstract

The expanding use of biologic and targeted immunomodulatory therapies has been accompanied by an increasing number of reports of opportunistic ocular infections. Cytomegalovirus (CMV) retinitis (CMVR), in particular, has recently been reported after exposure to several Janus kinase (JAK) inhibitors, raising concern about a potential class-related ocular safety signal. We report a case of CMVR following exposure to golidocitinib, a selective JAK1 inhibitor, in an immunocompromised patient without human immunodeficiency virus (HIV) infection, in whom undetectable plasma CMV DNA contributed to delayed diagnosis. A 62-year-old HIV-negative man with relapsed primary cutaneous T-cell lymphoma (CTCL) and diabetes developed CMV viremia after four cycles of a golidocitinib-containing regimen. Golidocitinib was discontinued, and intravenous ganciclovir rendered plasma CMV DNA undetectable. During maintenance antiviral therapy, he developed progressive bilateral visual loss while weekly plasma testing remained negative. Early fundus photographs showed the classic “ketchup-and-cheese” appearance of fulminant CMVR, but diabetic retinopathy was diagnosed because of his diabetes and negative plasma CMV DNA result. This misdiagnosis delayed treatment for one month. At referral, visual acuity was hand motion in the right eye and 20/133 in the left eye, with severe vitritis, retinal vascular whitening, and disruption of the retinal layers. Subsequent intraocular fluid testing showed a vitreous CMV DNA level of 4.25 × 10 4 copies/mL, and targeted next-generation sequencing detected CMV. Subsequent systemic and intravitreal ganciclovir controlled the retinitis, but vision did not recover. To the best of our knowledge, this is the first published case report describing CMVR occurring after golidocitinib therapy. Undetectable plasma CMV DNA does not exclude compartmentalized ocular infection and should not delay intraocular fluid testing when necrotizing retinitis is suspected.

BMC Ophthalmology
Fudan University (CN), Huashan Hospital (CN)
Good health and well-being
Cytomegalovirus and herpesvirus research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon